UNC9975

CAS No. 1354030-19-5

UNC9975( —— )

Catalog No. M34459 CAS No. 1354030-19-5

UNC9975 is a beta-inhibitory protein-biased dopamine D(2) receptor agonist with antipsychotic activity and can be used to study neurologic disorders such as schizophrenia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 686 In Stock
10MG 938 In Stock
25MG 1444 In Stock
50MG 1841 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UNC9975
  • Note
    Research use only, not for human use.
  • Brief Description
    UNC9975 is a beta-inhibitory protein-biased dopamine D(2) receptor agonist with antipsychotic activity and can be used to study neurologic disorders such as schizophrenia.
  • Description
    UNC9975 is a beta-inhibitory protein-biased dopamine D(2) receptor agonist with antipsychotic activity and can be used to study neurologic disorders such as schizophrenia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    Dopamine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1354030-19-5
  • Formula Weight
    463.4
  • Molecular Formula
    C23H28Cl2N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1N=C2NC(OCCCCN3CCN(C=4C=CC=C(Cl)C4Cl)CCC3)=CC=C2CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • ONC206

    ONC206 is an analogue of TRAIL inducer ONC201 and is a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations. ONC206 also has broad-spectrum anti-tumor activity. ONC206 (Oncoceutics) is an imipiridone with nanomolar potency and analogue of ONC201, a selective dopamine receptor D2 (DRD2) antagonist currently being investigated in phase II clinical trials for serous endometrial cancer (SEC).??

  • FAUC-213

    FAUC-213 is a selective full antagonist of the dopamine D4 receptor.

  • BP 897

    2-Naphthalenecarboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- is a potent and selective dopamine D3 receptor agonist, and a weak dopamine D2 receptor antagonist.